Healthcare entity
Every one of those 1 sits in a single category, market-trends. Relyvrio is most often covered alongside Amylyx Pharmaceuticals, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Relyvrio appears in 1 tracked Healthcare story from August 18, 2026.
Last mentioned: 5d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Relyvrio is most often covered alongside Amylyx Pharmaceuticals, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Relyvrio appears in 1 tracked Healthcare story from August 18, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 11 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Relyvrio. Shared-story counts are live from our verified record — not editorial picks.
A late-stage trial found Amylyx's once-daily injection avexitide reduced hypoglycemic episodes by 55% in people with post-bariatric hypoglycemia, a condition with no approved treatments. The drug was well tolerated, and the company plans a U.S. filing by end of 2026. For health systems and clinicians, the result signals a potential first-ever standard therapy that could change post-bariatric care.
Source: arynews.tv · medscape.com
Relyvrio is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
